Aribio Publishes Study on Low-Frequency Vibration Brain Stimulation Effects in SCI-Level International Journal

Aribio, which is in the process of merging with Solux, announced on the 10th that it published research results on the effects of low-frequency vibration brain stimulation in the SCI-level academic journal Brain Research Bulletin.

The research team applied 40 Hertz (Hz) vibration for 30 minutes over 3 days to cells damaged by the neurotoxic protein beta-amyloid (Aβ). As a result, low-frequency vibration stimulation suppressed the negative effects of beta-amyloid, significantly increasing cell survival rates compared to the control group. Additionally, certain proteins that activate autophagy increased, inhibiting brain cell damage, and inflammatory substances in microglia were significantly reduced, aiding anti-inflammatory effects. By decreasing the calcium ion concentration in perivascular cells elevated by beta-amyloid, it is expected to help improve cerebral blood flow.

The company evaluated that this paper scientifically demonstrated the effectiveness of low-frequency vibration stimulation technology applied directly to the head. They explained that in the field of Alzheimer's disease, where there is no definitive treatment, a non-drug and non-invasive approach using low-frequency vibration stimulation has high potential.

Aribio has also succeeded in developing non-drug products utilizing low-frequency vibration stimulation technology. They have started marketing the homecare wellness product for brain health and cognitive function, "Inji Doctor Herzion," and are negotiating exports with countries such as Japan and Germany. Inji Doctor Herzion is a product that uses ultra-small acoustic vibration stimulation technology to help cognitive health, improve depression, provide psychological stability, and enhance concentration.

Clinical trials for approval as an electronic medicine are also underway. Clinical trials are being conducted at Bundang Seoul National University Hospital targeting early Alzheimer's patients, and additional clinical trials are being conducted with the Gwangju Dementia Cohort Research Group, Asian Dementia Foundation, and Chosun University Hospital to verify efficacy and utility from multiple perspectives.

Shin Chang-ho, head of Aribio’s Digital Health Team, said, "The patented low-frequency vibration stimulation technology has high potential to be used in various product lines that slow cognitive decline and support overall cognitive health," adding, "Innovative devices like Inji Doctor Herzion will present a new paradigm in the global digital healthcare market."